Contact
13 Mar 24
News
13 Mar 24
Biocomposites announces approval of STIMULAN in Brazil as an antibiotic carrier for treating bacterial infection
    STIMULAN, when mixed with antibiotics, can be used for the treatment of bacterial infection
    STIMULAN® will be distributed exclusively by Bone Surgical in Brazil
Keele, UK, 13 March 2024 – Biocomposites, an international medical devices company that engineers, manufactures and…...
7 Feb 24
News
7 Feb 24
Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.
  • BLADE-VG2 trial will evaluate the safety and efficacy of STIMULAN VG to treat diabetic foot osteomyelitis
  • BLADE-OPU2 will evaluate the safety and efficacy of STIMULAN VG to treat stage IV pressure ulcers
  • Keele, UK, 7 February 2024 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    16 Jan 24
    News
    16 Jan 24
    Biocomposites expands its international presence by opening new sales and distribution office in Italy
  • Biocomposites SRL will support sales of STIMULAN, NanoBone, genex and SYNICEM Spacers throughout Italy
  • New team has been hired and first sales have already taken place
  • Keele, UK, 16 January 2024 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    4 Jan 24
    News
    4 Jan 24
    Biocomposites’ investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2
  • RENOVITE® BMP-2 is being developed as an alternative to bone graft materials for interbody spinal fusion
  • It is the first product based on RENOVITE®, Renovos’ novel nanoclay therapeutic delivery platform for precision regenerative medicine
  • Keele, UK, 4 January 2024 - Biocomposites, an international medical devices company that engineers, manufactures and…...
    13 Dec 23
    News
    13 Dec 23
    Biocomposites exceeds revenue expectations and takes a big step forward in its research and development
  • New record for sales growth and number of patients supported
  • Product portfolio enhanced through acquisition of NanoBone® and expansion of STIMULAN® approval as an antibiotic carrier to treat bacterial infection
  • Research and Development boosts with STIMULAN VG moving to phase II clinical trial and investment in Renovite
  • Keele, UK, 13 December 2023 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    21 Nov 23
    News
    21 Nov 23
    Biocomposites expands its product portfolio with the launch of SYNICEM™ spacers in the UK
  • SYNICEM™ hip, knee and shoulder spacers are preformed and loaded with gentamicin to maintain space and aid treatment of infection
  • Already successfully used in UK patients as part of their infection treatment strategies
  • Keele, UK, 21 November 2023 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    11 Oct 23
    News
    11 Oct 23
    Biocomposites announces new territories approved to promote STIMULAN­® as an antibiotic carrier in bone and soft tissue
    Argentina and Taiwan added to list of approved territories

    STIMULAN gives surgeons the freedom to choose the antibiotics that support their infection treatment strategy

    Keele, UK, 11 October 2023 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    6 Jun 23
    News
    6 Jun 23
    Biocomposites adds proprietary NanoBone® technology to its portfolio through the acquisition of Artoss GmbH
    NanoBone® technology complements Biocomposites’ absorbable bone regeneration products

    Artoss to benefit from Biocomposites established, global distribution network

    Keele, UK, 6 June 2023 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    5 Jul 23
    News
    5 Jul 23
    Biocomposites invests in Renovos Biologics – developers of the RENOVITE® nanoclay therapeutic delivery platform

    RENOVITE ® nanoclay is a novel therapeutic delivery platform for precision regenerative medicine

    Investment will help fund pre-market approval for use in spine, trauma and orthopaedics

    Biocomposites, CEO, Michael Harris will join Renovos Biologics Board of Directors

    Keele, UK, 5 July 2023 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    Introducing STIMULAN® to
    Podiatrists and Tissue Viability Nurses

    Diabetic foot osteomyelitis and diabetic foot ulcers
    can be challenging to heal. Find out how STIMULAN can help.

    STIMULAN®

    The only calcium matrix approved for mixing with vancomycin, gentamicin and tobramycin for use in bone and soft tissue.

    Explore our library

    Our industry leading knowledge, dedication and experience is supported with over 400 peer
    reviewed papers, presentations and posters.

    Pioneering calcium compounds

    Innovation is at the very heart of what we do, resulting in over 100 grants and registrations.

    Your specialty

    Access case studies, clinical and pre-clinical papers for musculoskeletal infection, trauma and spine to see how we are innovating across a wide range of clinical applications to help surgeons and their patients.

    Musculoskeletal infections

    Musculoskeletal infections, including infected non-unions, osteomyelitis and periprosthetic joint infections, are one of the biggest healthcare challenges of the 21st century.

    As the rapid growth of antibiotic-resistant strains and biofilms continues to outpace the development of new antibiotics and antibiotic strategies, care delivery is becoming increasingly challenging and complicated.

    Spine

    The popularity of spine surgery differs around the world. The number of procedures performed in the USA is double the number performed in Western Europe, Canada and Australia combined, and five times the number in the UK.

    In the USA, the number of spinal fusion procedures increased by 64% between 2002 and 2014, from approximately 268,000 to 414,000. The average cost per procedure has increased from $15,868 to $28,954 over the same period and was more than $12 billion in total in 2014.

    Why Biocomposites?

    At Biocomposites, we are pioneering calcium compound devices to regenerate and repair bone and soft tissue. With over 30 years’ experience of manipulating the surface chemistry and crystalline properties of calcium compounds, we engineer and manufacture products at the forefront of calcium technology.

    • Singular focus
    • Proprietary technology
    • Dedicated to quality
    Learn more